CCO Independent Conference Highlights of the 2024 ASCO Genitourinary Cancers Symposium *

Review an expert preview commentary, download Capsule Summary slidesets, and read an expert analysis text module highlighting key studies from the 2024 Genitourinary Cancers Symposium.

Share

Program Content

Activities

ASCO GU 2024: Key Studies
An Expert’s Guide to Key Studies at the 2024 ASCO Genitourinary Cancers Symposium
Clinical Thought
Conference Coverage
Congratulations: You achieved a completion on 04/09/2022

Released: January 24, 2024

View Activity
7 Capsule Summary Slidesets

Activities

BRCAAway Phase II Trial
BRCAAway: Phase II Trial of Abiraterone, Olaparib, or Abiraterone + Olaparib in HRR-Mutant Metastatic CRPC
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: January 30, 2024

View Activity
CONTACT-02
CONTACT-02: Cabozantinib + Atezolizumab vs Second Novel Hormonal Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: January 31, 2024

View Activity
Erdafitinib and EV Sequencing in aUC
Erdafitinib and Enfortumab Vedotin Sequencing in Patients With FGFR2/3-Altered aUC: UNITE Database Retrospective Analysis
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: February 01, 2024

View Activity
EV-302/KEYNOTE-A39
Phase III EV-302/KEYNOTE-A39: Subgroup Analyses of EV + Pembrolizumab vs Chemotherapy in Previously Untreated Adv Urothelial Carcinoma
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: February 01, 2024

View Activity
KEYNOTE-564
KEYNOTE-564: Updated Analysis of a Phase III Trial of Adjuvant Pembrolizumab vs Placebo After Nephrectomy for Clear Cell Renal Cell Carcinoma
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: February 02, 2024

View Activity
PemCab in aUC
PemCab: Phase II Study of First-line Cabozantinib + Pembrolizumab for Cisplatin- or Platinum-Ineligible Patients With aUC
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: February 02, 2024

View Activity
A031501 AMBASSADOR
A031501 AMBASSADOR: Phase III Trial of Pembrolizumab vs Observation as Adjuvant Therapy for High-Risk Muscle-Invasive Urothelial Carcinoma
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: February 02, 2024

View Activity

Faculty

cover img faculity

Terence Friedlander, MD

Professor of Medicine and Robert and Virginia O’Reilly Family Endowed Chair
Chief, Zuckerberg San Francsico General Hospital
Division of Hematology/Oncology
Helen Diller Family Comprehensive Cancer Center
University of California, San Francisco
San Francisco, California

cover img faculity

Rana R. McKay, MD

Associate Professor of Medicine
Division of Hematology/Oncology
Department of Medicine
University of California, San Diego
Genitourinary Oncology Team Lead
Moores Cancer Center
La Jolla, California

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC.

Supporters

Supported by educational grants from AstraZeneca, Exelixis, Inc., and Janssen Biotech, Inc. administered by Janssen Scientific Affairs, LLC.

AstraZeneca

Exelixis, Inc.

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.